Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Herpes simplex candidate (gD) vaccine GSK208141
Herpes simplex candidate vaccine GSK208141 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group A | EXPERIMENTAL | - |
| Group B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Herpes simplex candidate (gD) vaccine GSK208141 | BIOLOGICAL | Intramuscular injection, 2 doses, 2 different formulations (with and without MPL) |
Inclusion Criteria: * Between 18 and 40 years of age * Seropositive for antibodies against HSV * Female volunteers must have been using contraceptives for at least 2 months before the entry and should avoid becoming pregnant for the duration of this study. * Good physical condition as established b...
GSK208141 is an investigational vaccine developed by GSK plc for herpes simplex. It is a Phase 1 candidate studied in healthy adults who were already herpes simplex virus-positive. The program has completed one Phase 1 trial with 16 participants and is not currently listed as having active trials.
GSK208141 is being studied for herpes simplex, the viral infection caused by herpes simplex virus. The completed Phase 1 trial enrolled healthy herpes simplex virus-positive adults, so the candidate was evaluated in people already carrying the virus rather than as a preventive vaccine in uninfected volunteers.
GSK208141 is developed by GSK plc, which trades under the ticker GSK. The candidate is part of the company's infectious disease pipeline and is described as a vaccine modality. The single registered trial, NCT00698893, was sponsored and completed under GSK.
GSK208141 is in Phase 1 development. One Phase 1 trial has been completed, and no active trials are listed. The study was a controlled Phase 1 evaluation of the candidate gD vaccine, with or without MPL, in healthy herpes simplex virus-positive adults.
GSK208141 has been studied in one completed Phase 1 trial, NCT00698893, titled Evaluation of Safety of Candidate gD Vaccine, With or Without MPL in Healthy Herpes Simplex Virus-positive Adults. The trial enrolled 16 participants aged 18 years and older, of all sexes, and was controlled but not randomized or double-blind.
Yes, GSK208141 is also known as the herpes simplex candidate (gD) vaccine GSK208141. The gD designation refers to the glycoprotein D component described in the candidate's name. Both names refer to the same GSK plc Phase 1 vaccine candidate for herpes simplex.